Image

Europe Stem Cell Therapy Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Europe
  • 350 Pages
  • No of Tables: 90
  • No of Figures: 42

Europe Stem Cell Therapy Market, By Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors) Industry Trends and Forecast to 2029

Europe Stem Cell Therapy Market

Market Analysis and Size

Chronic diseases-including cancer, musculoskeletal disorders and neurology disorders, chronic injuries, cardiovascular and gastrointestinal-can lead to hospitalization, long-term disability, reduced quality of life, and death.

Stem Cell Therapy Market

 

Europe Stem Cell Therapy Market

The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung, and spinal cord injuries, and improve the state of autoimmune diseases, liver, and bone and cartilage diseases. Stems cells are a potent tool for the treatment of infections caused by inflammation, immune system failure, and, or tissue degeneration.

The drivers responsible for the growth of the Europe stem cell therapy market are the increased incidence of chronic diseases, rise in GMP-certification approvals for cell therapy production facilities, growing biotechnology sector and rise in clinical trials for stem-cell-based therapies. However, factors that are expected to restrain the market growth are the rise in the cost of stem cell-based research, and the risks faced while undergoing stem cell therapy, and the availability of alternatives.

The Europe stem cell therapy is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the Europe stem cell therapy market is expected to reach the value of USD 8.15 million and grow at a CAGR of 10.0% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Year

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors)

Countries Covered

Italy, Belgium, Czech Republic, Germany, U.K., Spain, Hungary, and Poland

Market Players Covered

Takeda Pharmaceutical Company Limited, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Orthofix Medical Inc., BioRestorative Therapies, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc., among others

Market Definition

Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.

Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.

Europe Stem Cell Therapy Market Dynamics

Drivers

  • Rise in prevalence and incidence of chronic diseases

Chronic diseases are common health conditions around the world. In Europe, one in three adults suffers from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens. Chronic diseases—including cancer, musculoskeletal disorders and neurology disorders, chronic injuries, cardiovascular and gastrointestinal—can lead to hospitalization, long-term disability, reduced quality of life, and death.

The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung and spinal cord injuries, and improve the state of autoimmune diseases, liver, and bone and cartilage diseases. Stem cells are a potent tool for treating diseases caused by inflammation, immune system failure, and or tissue degeneration.

For instance,

  • In 2021, according to the World Health Organization (WHO), approximately 1.7 billion people were down with musculoskeletal disorders worldwide. Low back pain causes a high burden of musculoskeletal disorders.
  • Rise in research and development and availability of funding for stem cell research

The stem cell research is funded by the National Institute of Health (NIH) budget. The private sector also funds stem cell research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With stem cell therapies being such a new field, an unbiased governmental body must supervise them. The FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries.

For instance,

  • In December 2021, in the U.K., the MRC and Biotechnology and BBSRC funded the U.K. Stem Cell Bank to carry out research projects for ethically approved, quality controlled, and assured repository of human embryonic, fetal and adult stem cell lines.
  • Rise in GMP certification approvals for cell therapy production facilities

GMP ensures that products are consistently produced and controlled to state-of-the-art quality standards appropriate to their intended use. Thus, GMP principles significantly contribute to providing consumers and patients with products with consistent quality and high safety levels.

The GMP certification received would result in the prevention of errors. The accreditation received allows the manufacturers to produce cell lines in an identical, repeatable, sterile environment. Therefore, the GMP certification may boost the Europe stem cell therapy market growth.

Opportunities

  • The rise in healthcare expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

For instance,

  • In 2020, according to Eurostat, the health expenditure in the European Union amounted to USD 1,309.6 million
  • Strategic initiatives by market players

The demand for stem cell therapy has increased the demand in Europe owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.

Restraints/Challenges

  • The rise in cost of stem-cell based therapy research

Stem cell therapy is a developing and novel treatment option for treating several disorders. Sometimes, the cost of the therapy is a concern for several conditions. The stem-cell therapy treatment procedures. The stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. The cost of stem cell therapy-based research therapy is not covered by medical insurance. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend.

For instance,

  • In 2021, the data by Gift of Life, a U.K. sister charity to Podari Zhizn, stated that the cost of stem cell therapy for musculoskeletal disorders is USD 4861.44 to USD 5401.60
  • The risks faced while undergoing stem cell therapy

Specific risks are observed by stem cell therapists and research scientists while developing the stem cell therapeutic models. The main challenge faced while using stem cell therapy is optimal cell sourcing. Stem cell therapy is well established and rapidly growing in developed countries; however, certain risks shield the growth of this therapy in developing countries. The criteria limit the use of stem cell therapy. Hence, there are certain risks observed for patients undergoing stem cell therapy.

For instance,

  • The risks faced while undergoing stem cell therapy are genetic instability, tumor formation, inappropriate stem cell formation, immune rejection of transplanted stem cells, hemorrhage during neurosurgery, and postoperative infection
  • The risks faced after stem cell transplantation is improper distribution and localization of stem cell after transplant. Pluripotent stem cells can form teratoma (tumor)
  • Stringent regulations

The regulatory guidelines for stem cell therapeutics are strict compared to older ones. The manufacturers have to make specific product changes before approval, which is expected to cause delays. The companies have to carefully review the product specifications and certifications before categorizing their product according to the Food and Drug Administration (FDA) and the European Union (E.U.). Every country has its regulatory authority responsible for enforcing rules and regulations for drug development, licensing, registration, manufacturing, marketing, and labeling of pharmaceutical products.

FDA's Center for Biologics Evaluation & Research (CBER) regulates human tissues, cells, and tissue-based products intended for transplantation, including hematopoietic stem cells.

For instance,

  • In the U.K., the Medicines and Healthcare Products Regulatory Agency (MHRA) regulates and provides guidelines for stem cell therapy; when stem cell therapy is considered to be a Medicinal Product (M.P.), for quality and safety (Q and S), testing regulations

The Europe stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on t   Europe stem cell therapy market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The Europe stem cell therapy market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables available in the report. Direct or indirect impact analyses of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market during the growth period.

Impact of COVID-19 on the Europe Stem Cell Therapy Market

During the pandemic, stem cell therapy had a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for stem cell therapy in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during COVID-19.

Recent Development

  • In September 2020, Takeda Pharmaceutical Company Limited. had received product approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) and adipose-derived mesenchymal stem cells for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's disease (CD). The approval received would result in post-market approval and product launch. This is expected to increase the market growth.

Europe Stem Cell Therapy Market Scope

The Europe stem cell therapy market is segmented into five segments based on product type, type, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Bone Marrow Derived Mesenchymal Stem Cells
  •  Placental or Umbilical Stem Cell
  •  Adipose Tissue Derived Mesenchymal Stem Cells
  •  Others

On the basis of product type, the Europe stem cell therapy market is segmented into bone marrow derived mesenchymal stem cells, placental or umbilical stem cell, adipose tissue derived mesenchymal stem cells, and others.

Type

  • Allogeneic Stem Cell Therapy
  •  Autologous Stem Cell Therapy

On the basis of type, the Europe stem cell therapy market is segmented into allogenic stem cell therapy, and autologous stem cell therapy.

Application

  • Musculoskeletal Disorders
  • Wounds and Injuries
  • Acute Graft-Versus-Host Disease (AGVHD)
  • Surgeries
  • Gastrointestinal Diseases
  • Cardiovascular Diseases
  • Others

On the basis of application, the Europe stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, and others.

End User

  • Hospitals and Surgical Centers
  •  Therapeutic Companies
  •  Services Companies
  •  Others

On the basis of end user, the Europe stem cell therapy market is segmented into hospitals and surgical centers, therapeutic companies, services companies, and others.

Distribution Channel

  • Direct Tenders
  • Third Party Distributors

Stem Cell Therapy Market_Market

On the basis of distribution channel, the Europe stem cell therapy market is segmented into direct tender, and third party distributors.

Europe Stem Cell Therapy Market Regional Analysis/Insights

The Europe stem cell therapy market is analyzed, and market size insights and trends are provided by regions, product type, type, application, end user, and distribution channel, as referenced above.

Some of the countries covered in the Europe stem cell therapy market report are Italy, Belgium, the Czech Republic, Germany, the U.K., Spain, Hungary, and Poland. Italy is expected to dominate the market due to a rise in approval for clinical trials in stem cell research and developments in the field of human stem cells.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Stem Cell Therapy Market Share Analysis

The Europe stem cell therapy market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Europe stem cell therapy market.

Some of the major players operating in the Europe stem cell therapy market are Takeda Pharmaceutical Company Limited, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Orthofix Medical Inc., BioRestorative Therapies, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or can drop down your inquiry. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe versus Regional, and Vendor Share Analysis. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands' understanding of the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you with data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 2 EUROPE BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 20 EUROPE HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 25 EUROPE DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 28 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 29 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 33 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 ITALY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 36 ITALY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 ITALY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 ITALY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 39 ITALY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 40 ITALY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 ITALY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 BELGIUM STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 43 BELGIUM STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 BELGIUM ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 BELGIUM AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 BELGIUM STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 47 BELGIUM STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 BELGIUM STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 49 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 50 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 CZECH REPUBLIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 52 CZECH REPUBLIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 53 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 54 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 55 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 56 GERMANY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 57 GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 GERMANY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 GERMANY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 GERMANY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 61 GERMANY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 62 GERMANY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 63 U.K. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 64 U.K. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 U.K. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 66 U.K. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 67 U.K. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 68 U.K. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 69 U.K. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 70 SPAIN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 71 SPAIN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 SPAIN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 SPAIN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 SPAIN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 75 SPAIN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 SPAIN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 HUNGARY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 78 HUNGARY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 HUNGARY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 80 HUNGARY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 HUNGARY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 82 HUNGARY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 HUNGARY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 84 POLAND STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)

TABLE 85 POLAND STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 POLAND ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 POLAND AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 88 POLAND STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)

TABLE 89 POLAND STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 90 POLAND STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions